Aravive Inc
Change company Symbol lookup
Select an option...
ARAV Aravive Inc
CBU Community Bank System Inc
FPA First Trust Asia Pacific Ex-Japan AlphaDEX® Fund
GER Goldman Sachs MLP and Energy Renaissance Fund
FNX First Trust Mid Cap Core AlphaDEX® Fund
FNK First Trust Mid Cap Value AlphaDEX® Fund
FMK First Trust Mega Cap AlphaDEX® Fund
FLN First Trust Latin America AlphaDEX® Fund
FKU First Trust United Kingdom AlphaDEX® Fund
FKO First Trust South Korea AlphaDEX® Fund
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.

Closing Price
$8.26
Day's Change
0.4248 (5.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.28
Day's Low
7.82
Volume
(Above Average)
Volume:
43,249

10-day average volume:
39,089
43,249

Thinking about buying stock in Apple, Axsome Therapeutics, Luxoft, Netflix or QEP Resources?

9:31 am ET January 8, 2019 (PR Newswire) Print

InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, LXFT, NFLX, and QEP.

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

-- AAPL: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=AAPL&prnumber=010820190

-- AXSM: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=AXSM&prnumber=010820190

-- LXFT: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=LXFT&prnumber=010820190

-- NFLX: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=NFLX&prnumber=010820190

-- QEP: https://www.investorsobserver.com/pr-stocks-lp/?stocksymbol=qep&prnumber=010820190

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

https://c212.net/c/img/favicon.png?sn=CG17737&sd=2019-01-08

View original content:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-apple-axsome-therapeutics-luxoft-netflix-or-qep-resources-300774722.html

SOURCE InvestorsObserver

https://rt.prnewswire.com/rt.gif?NewsItemId=CG17737&Transmission_Id=201901080931PR_NEWS_USPR_____CG17737&DateId=20190108

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.